Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days
Its concurrent engagement of GLP-1R, GIPR, and GCGR distinguishes it structurally and pharmacologically from both selective GLP-1R agonists such as semaglutide and dual GLP-1R/GIPR agonists such as tirzepatide
February 1, 2024
Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ
McEwan, P
This approach allows patients to monitor their initial response to the medication, particularly any gastrointestinal side effects such as nausea or diarrhoea, without the added stress of work obligations or important social events